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ABSTRACT  
 
Objective: The objective of this systematic review is to determine whether or not Epidermal 
Growth Factor Vaccine also known as CimaVax-EGF is more effective at improving survival 
than best supportive care or other therapies in patients with non-small cell lung cancer. 
 
Study Design: Systematic review of two randomized control trials (RCTs) and one 
observational/before and after study published after the year 2007.  
 
Data Sources: All articles were published in English in peer reviewed journals and were searched 
for personally by me, the author, via PubMed and Embase. Articles selected were only those that 
were published after 2007, were relevant to my clinical question and addressed patient oriented 
outcomes that mattered.  
 
Outcomes Measured: Primary outcome measured was overall survival as estimated in months or 
measured in years. Secondary outcome measured was safety as estimated by percent of patients 
experiencing any adverse effects and/or specific adverse reactions.  
 
Results: Both Rodriguez et al and Vinageras et al claim that Epidermal Growth Factor vaccine 
improves overall survival in patients with stage IIIB/IV NSCLC based on the results of their 
RCTs (Rodriguez et al 343 patients total assessed for efficacy, p = 0.036, 5 year survival in 
vaccinated 16.62% vs control 6.2% NNT = 10, Vinageras et al 74 patients total assessed for 
efficacy, p = 0.0124, 1 year survival in vaccinated 67% vs. control 33% NNT = 3). Kananathan 
made no claims about efficacy but claimed survival rates indicated the need for a randomized 
control trial to determine efficacy (23 patients assessed for efficacy, 1 year survival = 91% 5 year 
survival = 9%). All three studies found the vaccine to be safe and well tolerated.  
 
Conclusions: Although both RCTs claim the EGF vaccine improves survival in Stage IIIB/IV 
NSCLC patients, risk of bias in study design (not blinded, use of other therapies) and quality of 
data reported (not reporting some censored patients, overlap of CIs) limit efficacy claims as does 
the number of studies reviewed. Large double blinded studies are needed to study efficacy.  
 
Key Words:  Epidermal Growth Factor (EGF) vaccine and non-small cell lung cancer, CimaVax-
EGF and non-small cell lung cancer 
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INTRODUCTION  
 Lung cancer is the leading cause of cancer death in the world, with non-small cell lung 
cancer (NSCLC) accounting for 85% of lung cancers in the United States.
1,2  
 
 In 2017, the estimated number of new cases of NSCLC are 222, 500 and the estimated 
number of deaths from NSCLC are 155, 870.
3
 An estimated 13.6 billion dollars were spent 
nationally for lung cancer in 2016.
4
 In 2006, nearly half a million hospital stays included lung 
cancer as a diagnosis with almost 28% citing lung cancer as the primary reason for the stay.
5 
 
The cause of NSCLC (and lung cancer in general) is thought to be largely due to 
environmental exposure to carcinogens with individual susceptibility to carcinogens and 
presence or absence of protective factors playing a minor role. Cigarette smoking in particular 
accounts for about 85% of lung cancers in the U.S.
2 
 
Surgical resection of NSCLC tumors is typically considered first line treatment, 
particularly in early stages. Radiation therapy and/or chemotherapy pre or post operatively or as 
part of first line treatment for late stages are also commonly used. Prophylactic cranial irradiation 
is used to reduce incidence of brain metastases. Identification of mutations, particularly in the 
EGFR, MAPK, PI3K signaling pathways, has led to targeted therapy that addresses 
abnormalities in these pathways and associated drug resistance.
3
  
 Some of the mentioned treatments may in some cases provide a cure, particularly in early 
stages, and may in some cases prolong survival, however 1 year survival for patients with 
NSCLC with wild type tumors was 35% and 5 year survival was 5%.
6 
Epidermal growth factor 
has been shown to promote cancer cell growth and proliferation and patients with NSCLC with 
overexpression of this factor have been shown to have a poorer prognosis. A vaccine known as 
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the Epidermal Growth Factor vaccine has therefore been developed with the goal of prolonging 
survival by inducing autoimmunity against this self-protein.
6
  
 
 This paper evaluates two randomized control trials (RCTs) and one observational/before 
and after study investigating the efficacy of Epidermal Growth Factor Vaccine as a treatment for 
NSCLC as measured by overall survival.  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not Epidermal Growth 
Factor Vaccine also known as CimaVax-EGF is more effective at improving survival than best 
supportive care or other therapies in patients with non-small cell lung cancer.  
METHODS 
 Criteria used for selection of studies were as follows: addressed the population of patients 
with NSCLC, used Epidermal Growth Factor (EGF) vaccine also known as CimaVax-EGF as an 
intervention, used supportive care and/or other therapies as comparisons, measured overall 
survival, and were either randomized control trials or observational/before and after studies.  
 Key words used for searching articles were Epidermal Growth Factor (EGF) vaccine and 
non-small cell lung cancer, CimaVax-EGF and non-small cell lung cancer. All articles searched 
were published in English and all articles were published in peer-reviewed journals. The search 
databases used were PubMed and Embase. Articles were selected based on their relevance to my 
clinical question and if they included patient oriented outcomes (POEMs).   
 The inclusion criteria for selection were RCTs or observational/before and after studies 
published after 2007. The exclusion criteria for selections were studies published 2007 or earlier, 
studies that did not measure POEMs.  
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 Statistics reported in the articles were median survival estimates, 95% CIs, p-values, 
hazard ratios. Statistics calculated by author were RBI, ABI, NNT, RRI, ARI, NNH.
6,7,8
  
 See Table 1 for demographics and characteristics of included studies.  
Table 1: Demographics and Characteristics of Included Studies  
Study 
and 
Type  
# of pts, 
Age in 
years  
Inclusion Criteria Exclusion 
Criteria  
W
/D 
Interventions  
Rodrigue
z 
2016
7 
 
RCT 
 405 pts 
 Ages not 
listed but 
articles 
mentions 
pts 
matched 
for age 
 
 Patients 18 or older with histologically 
or cytologically proven stage IIIB/IV 
NSCLC and an ECOG performance 
status of 0-2  
 Patients with all NSCLC subtypes and 
life expectancy of at least 3 months  
 Hemoglobin values ﹥90 g/L 
 Leukocytes count ≥ 3.0 x 109 /L  
 Platelet count  ≥ 150 x 109 /L 
 Aspartate aminotransferase and alanine 
aminotransferase up to 2.5X the upper 
institutional limit 
 Creatinine up to 2X the upper 
institutional reference value  
 Received 4-6 cycles of platinum based 
chemotherapy ( mostly 
cisplatin/carboplatin in combination 
with vinblastine, etoposide or 
paclitaxel)  
 Had stable disease or objective disease  
Not listed 
in study  
54 2.4 mg of Epidermal 
Growth Factor (EGF) 
vaccine given IM at four 
injection sites (two 
deltoid and two gluteal) 
every 2 weeks for 4 
doses and then monthly 
thereafter as well as best 
supportive care with 200 
mg/m
2
 
cyclophosphamide given 
IV 72 hrs prior to first 
immunization  
 
Vinagera
s 2008
8 
 
RCT 
 80 pts 
 Median 
age 55.5 
 Pts older than 18 with histologically or 
cytologically proven non small cell 
lung cancer at stages IIIB/IV 
 ECOG performance status of at least 2 
 Adequate bone marrow reserve  
 WBC count of at least 3,000 per 
microliter 
 Platelet count of at least 100,000 per 
microliter  
 Hemoglobin of at least 10 g/dL 
 Life expectancy of longer than 3 
months  
 Normal creatinine, bilirubin, and 
transaminase according to each 
institutional standards  
 Pregnanc
y or 
lactation  
 Secondar
y 
malignan
cies 
 History 
of 
hypersen
sitivity 
to 
foreign 
proteins  
 
6  EGF vaccine on days 
1, 7, 14, 28 and 
monthly after with 200 
mg/m
2
 
cyclophosphamide 
given 3 days before 1st 
dose  
 External beam 
radiotherapy for 
palliative care  
 Supportive care if 
required  
 
Kananath
an  
2015
9
  
 
Observati
onal/ 
Before 
and After
 
 23 pts 
 Median 
age 55.18 
Patients with stage III/IV non small cell 
lung cancer  
 
Not listed  1 Four IM injections of 
Cimavax(EGF vaccine) 
given day 0, 14, 28, and 
every 28 days thereafter 
with 300 mg IV 
cyclophosphamide given 
72 hrs prior to first 
vaccination  
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OUTCOMES 
 The primary outcome measured in all three studies was overall survival, estimated in 
months by the Kaplan Meier method in the Rodrigues et al and Vinageras et al studies, 1 year 
survival for the Vinageras et al and Kananathan et al study studies, 2,3,4 year survival for the 
Kananathan et al study and 5 year survival by the Rodrigues et al and Kananathan et al studies. 
Safety was a secondary outcome measured as estimated by percentage of patients experiencing 
any and/or specific adverse events.
6,7,8
  
RESULTS  
Description of Studies  
 Rodriguez et al conducted a randomized control trial that started with 405 patients with 
stage IIIB and IV NSCLC, 270 of which were enrolled in the vaccination arm, 135 of which 
were enrolled in the control arm. Patients in the control arm were treated with best supportive 
care. The two arms were matched for gender, ethnic origin, smoking history, ECOG score, 
disease stage, tumor histology, and response to first line treatment. Of the 270 patients enrolled 
in the vaccination arm, 219 received four doses of the vaccine as per protocol (regimen necessary 
for vaccine induction) and were assessed for efficacy. In the control arm, 124 were assessed for 
efficacy. Reasons for dropout included death prior to completion of induction period, rapid 
worsening of performance status, other comorbidities as well as schedule violations and consent 
withdrawal.
6 
 Vinageras et al conducted a randomized control trial that initially involved 80 patients 
with stage IIB and IV NSCLC, 40 of which were enrolled in the vaccination arm and the other 
40 of which enrolled in the control arm. Patients in the control arm were treated with best 
supportive care. External beam radiotherapy was performed for symptomatic relief in both the 
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vaccine and control arm. The two arms were matched for age, gender, race, ECOG score, disease 
stage, tumor histology, prior treatment and response to chemotherapy. Six patients were removed 
from assessment, three from the vaccine arm and three from the control arm. Reason for 
nonassessibility was given as noncompliance with entry criteria and refusing participation after 
random assignment.
7 
 Kananathan et al conducted an observational/before and after study involving 23 patients 
with stage III or IV NSCLC all of which were vaccinated with CIMAvax (EGF vaccine). Age, 
ethnicity, gender varied among the group with a disproportionate number of male patients (16 
males to 7 females) and disproportionate number of Malaysian individuals (18 Malaysian 
compared to 2 Indonsesian, 2 Australian, and 1 Chinese patient). Additionally, patients were on 
different first line therapies simultaneously while receiving vaccination, with chemotherapy 
being the most common first line therapy (15 patients).
8 
Risk of Bias in Included Studies  
 Both the Rodriguez et al and Vinageras et al studies were controlled trials in which the 
control and treatment groups were similar in terms of demographics, and assignment of patients 
to treatments was randomized, however, the randomization allocation was not concealed from 
those enrolling in the study, clinicians and study workers were not kept blind to treatment which 
introduces the possibility of bias. The losses to follow up were less than 20%, and follow up of 
patients was sufficient long.
6,7  
Kananathan et al was an observational/before and after study. 
Men compared to women and individuals of Malaysian descent were disproportionally 
represented which are significant concerns for bias.
8
  
 Cyclophosphamide was given prior to first vaccine dose in the vaccine arm in both the 
Rodriguez et al and Vinageras et al studies but not given in the control group.
6,7
. In the 
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Rodriguez et al study, sixteen patients in the vaccine arm and nine patients in the control arm 
received other therapies with one patient in each arm receiving a drug known to increase survival 
in advanced stage NSCLC.
6
 A large number of patients in the Kananathan et al study received a 
variety of different first line treatments in addition to vaccination.
8
 These confound any efficacy 
claims by the study authors. 
 
Safety  
 Of the 270 patients enrolled in the vaccine arm in Rodrigues et al, 246 received at least 
one vaccine dose and were thus considered the safety population and used for safety analysis 
while 132 out of 135 patients in the control group were used for safety analysis (three patients in 
the control group withdrew consent). In the vaccine arm, 195 patients (78.3%) reported any 
adverse event while in the control arm, 73 patients (55.3%) reported any adverse event.
6 
The 
relative risk increase (RRI) is 0.416, the absolute risk increase (ARI) is 0.230, and the number 
need to harm (NNH) is 4 (see Table 2). The most common adverse events reported were 
injection site reactions, 46.6% in vaccine arm vs 0% in control arm, fever 36.5% in vaccine arm 
vs 7.6% in the control arm, dyspnea 31.7% in the vaccine arm vs 28.8 % in the control arm, 
vomiting 23.3% in the vaccine arm and 3.8% in the control arm, and headache 22.5% in the 
vaccine arm vs 6.8% in the control arm.
6
  
 Of the 40 patients enrolled in the vaccine arm in the Vinageras et al study, 40 were 
analyzed for safety and of the 40 patients enrolled in the control arm, 40 were analyzed for 
safety. The incidence of any adverse event in the vaccine and in the control arm was not 
reported, however the most common reported symptoms were fever, 25% in the vaccine arm and 
7.5% in the control arm, headache, 25% in the vaccine arm and 10% in the control arm, asthenia 
20% in the vaccine arm and 18% in the control arm, tremor 18% in the vaccine arm and 0% in 
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the control arm, and chills 18% in the vaccine arm and 0% in the control arm.
7
 The relative risk 
increase (RRI) for fever, the most common side effect, is 2.33, the absolute risk increase (ARI) is 
0.175, and the number need to harm (NNH) is 5 (see Table 2). 
 Kananathan et al simply report pain and chills with rigors as being the most common side 
effects.
8 
Table 2 – Relative Risk Increase, Absolute Risk Increase and Numbers Needed to Harm as 
Determined by Percent of Patients Experiencing One or More Adverse Events  
 
Study 
Control Event 
Rate (CER) 
Experimental 
Event Rate 
(EER)  
Relative risk 
increase (RRI) 
Absolute risk 
increase (ARI) 
Number needed 
to Harm (NNH)  
Rodriguez et al 0.553 0.783 0.416 0.230 4 
Vinageras et al 0.075 0.25 2.33 0.175 5 
 
Efficacy  
 In the study conducted by Rodriguez et al, in the per protocol population, median survival 
was 12.43 months (95% CI 10.42-14.45) in the vaccine arm and 9.43 months (95% CI 7.53-
11.33) in the control arm. Five year survival was 16.62% in the vaccine arm and 6.2% in the 
control arm. The authors conducted a standard, unweighted log-rank test on survival data and 
found HR 0.77, 95% CI 0.61-0.98, p = 0.036 and as such the survival difference was considered 
statistically significant.
6
 Using 5 year survival for the control arm as the control event rate and 5 
year survival for the vaccine arm as the experimental event rate, relative benefit increase (RBI) 
was 1.682, absolute benefit increase (ABI) was 0.104, and number needed to treat was 10 (refer 
to Table 3).  
 Of note, patients with higher than median serum Epidermal Growth Factor (EGF) 
concentrations that were vaccinated were found to have a statistically significant survival 
advantage over controls with the same EGF concentrations (HR 0.41 95% CI 0.25-0.67 P= 
0.0001). Median survival for this subset of vaccinated patients was 14.66 months (95% CI 8.34-
20.98) and 8.63 months for this subset of controls ( 95% CI 1.67-15.59). Five year survival in 
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this subset of vaccinated patients was 23% while 5 year survival in this subset of controls was 
0%. Additionally patients who were determined to have a good antibody response to the vaccine 
after the completion of the induction period were found to have a statistically significant survival 
benefit when compared to controls (median survival was 14.90 months in the vaccine arm vs 
8.86 months for the control arm (HR 0.638 95% CI 0.44-0.92 p = 0.017)).
6 
 In the study conducted by Vinageras et al, in the vaccine arm, median survival was 6.47 
months (mean survival 12.73 months) and in the control arm, median survival was 5.33 months 
(mean survival 8.52 months). These changes were not significant. A significant difference in 
survival however was found in patients 60 years old or younger. In vaccinated patients 60 years 
old or younger, median survival was 11.57 months (mean survival 18.53 months) while in the 
control arm, median survival was 5.33 months (mean survival was 7.55 months, P = 0.0124). 
One year survival rate was 67% for all vaccinated patients and 33% for controls. One year 
survival for patients 60 years old or younger was 75% in the vaccine arm and 25% for controls.
7 
Using 1 year survival in all age groups for the control arm as the control event rate and 1 year 
survival for the vaccine arm in all age groups as the experimental event rate, relative benefit 
increase (RBI) as 1.03, absolute benefit increase (ABI) was 0.34, and number needed to treat was 
3 (refer to Table 3). 
 Of note, just as in Rodriquez et al, there was a survival advantage found in  vaccinated 
patients determined to have a good antibody response compared to controls (median survival in 
vaccine arm was 11.7 months (mean 19.47 months) while median survival in control arm was 
5.33 months (mean 8.52 months). Additionally there was a survival advantage in vaccinated 
patients with good antibody response compared to vaccinated patients with poor antibody 
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response ( median survival in vaccinated patients with poor antibody response 3.6 months (mean 
4.49 months)).
7 
 In the study conducted by Kananathan et al, median survival was 21 months, mean 
survival was 30.2 months. Survival rate was 91% at 1 year, 43% at 2 years, 30% at 3 years, and 
9% at 5 years.
8 
Table 3 – Relative Benefit Increase, Absolute Benefit Increase and Numbers Needed to Treat as 
Determined by 5 year and 1 year survival  
 
 
Study 
Control Event 
Rate (CER) 
Experimental 
Event Rate 
(EER)  
Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Number needed 
to Treat (NNT) 
Rodriguez et al* 0.062 0.1662 1.680 0.104 10 
Vinageras et al** 0.33 0.67 1.03 0.34 3 
*Event is 5 year survival rate in decimal form  
**Event is 1 year survival rate in decimal form  
DISCUSSION  
Summary of Main Findings  
 Rodriquez et al found that there was a statistically significant survival advantage for 
patients vaccinated with the EGF vaccine (p = 0.036) while Vinageras et al found a statistically 
significant survival advantage in vaccinated patients only in patients 60 years old or younger. 
Furthermore, Rodriguez et al found a statistically significant advantage in survival for vaccinated 
patients with higher than median EGF concentrations in serum. Both Rodriquez et al and 
Vinageras et al found a survival advantage in vaccinated patients with good antibody response as 
determined by each trial’s criteria which was statistically significant in Rodrigues et al however 
no mention of statistical significance was made by Vinageras et al.
6,7
 Kananathan et al made no 
claims regarding efficacy as is appropriate since this study is an observational, not experimental 
study and therefore no claims about efficacy can be made from such a study. The authors simply 
comment that Phase III clinical trial results are necessary to determine efficacy.
8
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 In terms of safety, all three studies determined the vaccine to be well tolerated.
6,7,8
 
Interestingly, for the Rodriguez et al study, the NNH was lower than the NNT but the types of 
reported side effects would generally be considered reactions that do not threaten mortality or 
significantly affect overall quality of life as compared to the advantage of overall survival.  
Limitations of Evidence  
 Both Rodriguez et al and Vinageras et al used the Kaplan Meier method to estimate 
survival time and the standard log-rank test to compare survival between the vaccine and control 
groups which are appropriate and common for this type of data.  
 In Rodriguez et al, the small horizontal distances between data points in the Kaplan 
Meyer curves for survivorship indicate a large number of enrolled subjects suggesting the sample 
size is more likely to represent the true population. There are also a considerable number of 
censored subjects in these curves which indicates that the survivorship estimates may not be that 
accurate. Censored patients were not shown for the survivorship curves in the high EGF serum 
concentration subpopulation and no reason was given as to why which limits the reliability of 
this data. There is overlap of the confidence intervals (CIs) for median survival in months for the 
vaccinated and control groups in the entire population studied as well as in the subpopulation of 
patients with higher than median EGF serum concentrations, indicating that the true population 
median in the vaccinated and control groups is possibly the same or median survival is higher in 
the control group than in the vaccine group. The median survivals are however a snapshot in 
time and survival differences over time are best compared with the log rank test the results of 
which showed the data to be statistically significant. The CI for the hazard ratio (HR) (95% CI 
0.61-0.98) however indicates that the risk of death for vaccinated patients could be very close to 
the risk of death for control patients at any point in time (if population HR was 0.98). In the 
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subgroup of patients with higher than median EGF serum concentrations, CIs for median 
survival for both the vaccine and control groups were quite wide indicating a wide variability in 
overall survival within the group and/or a very small number of patients in this group. No CIs for 
median survival in months was reported for vaccinated patients with good antibody response as 
compared to the control group. It is important to keep in mind though that the vaccine and 
control group were not equal in terms of number of patients studied for efficacy, with about 
2/3rds of the total number of patients studies for efficacy belonging to the vaccine arm and only 
1/3
rd
 belonging in the control arm.  
 In the Vinageras et al study, censored patients are indicated in all the survivorship curves, 
and the number of censored patients appear to be few, however, this is a much smaller study than 
the Rodriguez et al study so to some extent that is expected. No CIs are reported for median 
survival in months, however both medians and means are reported. There was a large difference 
between the mean and medians of both the vaccinated and control groups when measuring 
survival in months for all patients indicating there are one or more outliers in the group that skew 
some of the date in the direction of increased survival.  
CONCLUSION 
 Although both RCTs claimed EGF vaccine to be effective in improving overall survival 
in patients with NSCLC, there is insufficient evidence to claim EGF vaccine is effective in 
improving survival because besides the obvious fact that this review only studies a very small 
number of studies, there are problems with the study designs (risk of bias) and quality of the 
evidence (nonreporting of censored patients, median survival CIs). Suggestions for future studies 
would be designing double blind randomized control trials. In the United States, the first Phase 
I/II randomized control trial is currently underway in the Roswell Park Cancer Institute.
9
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